Perceiv AI Partners with Alleo Labs to Optimize Clinical Trials Using Advanced AI and Prognostic Biomarkers
January 8, 2024 | San Francisco, USA
[San Francisco, January 8th 2024] – Perceiv AI, a leader in AI-driven precision medicine, today announced a strategic partnership with Alleo Labs, a pioneer in machine learning techbio company developing new therapeutics for neurological diseases, to de-risk and support the next clinical trial of Alleo. This collaboration will utilize Perceiv AI’s multimodal ForesightTM platform and prognostic biomarkers to select the most optimal patients for Alleo's upcoming clinical trials of ALO-001, a potential first-in-class deubiquitinating (DUB) enzyme inhibitor for treating Parkinson’s and Alzheimer’s disease.
The partnership marks a significant step in leveraging advanced AI to enhance clinical trial success. Perceiv AI’s Foresight platform, known for its ability to forecast disease progression in age-related diseases like Alzheimer's, will be instrumental in identifying suitable candidates for Alleo’s trials. This targeted approach aims to improve the success rate and efficiency of the trials by ensuring the inclusion of patients most likely to benefit from the treatments.
"Perceiv AI is at the forefront of transforming how clinical trials are conducted," said Christian Dansereau, PhD, CEO of Perceiv AI. "Our collaboration with Alleo Labs represents a groundbreaking approach to optimize patient selection, ultimately leading to more successful outcomes in the fight against brain diseases."
Alleo Labs combines large-scale computing with AI innovations in drug discovery to tackle challenges in treating brain diseases. "This partnership is a testament to our commitment to revolutionize precision medicine by applying AI at every facet of drug development," stated JL Ross, PhD., CEO of Alleo Labs. "By integrating Perceiv AI's prognostic capabilities with our machine learning software, we are poised to make significant strides in developing the next generation of treatments for Parkinson's and Alzheimer's."
To learn more about Perceiv AI, please visit www.perceiv.ai.
About Perceiv AI
Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform named Foresight to forecast disease progression in age-related diseases such as Alzheimer's disease. By providing a window into individual patients' disease progression, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses.
About Alleo Labs
Alleo Labs is pioneering machine learning solutions to advance precision medicine. Alleo merges data lakes, large-scale computing, and drug discovery to overcome challenges with drugging brain diseases. Supported by Nvidia, Alleo is developing machine learning software to systematically program small-molecules, and optimize the development of safer, more effective treatments for Parkinson's and Alzheimer's.